Legal status in the United States

Is GHK-Cu legal?

Read at FDA, DEA and WADAPublished by PepVault

GHK-Cu has no FDA-approved product, is not a federally controlled substance, and is not named on WADA’s Prohibited List (from January 1, 2027, its S0 class names peptides in general), as of November 18, 2026.

GHK-Cu at a glance

CheckStatus, read Nov 18, 2026
FDA approvalNot approved
CompoundingUnder FDA evaluation, not for injection (503A category 1)
DEA scheduleNot controlled
Sport (WADA)Not named; from 2027, S0 names peptides in general

FDA approval

GHK-Cu has no FDA-approved drug: Drugs@FDA lists no application for it.

A smiling man in a grey t-shirt in his living room, holding his phone

PepVault for iPhone

Keep your own record in PepVault

Log your doses and vials, with a reminder for the next one.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Compounding

FDA splits GHK-Cu by route. Its injectable form was in category 2 and its nominations were withdrawn. Its other routes (on the skin, for example) are back in category 1, substances under evaluation, on FDA’s list updated May 14, 2026, and FDA says it will ask its Pharmacy Compounding Advisory Committee about GHK-Cu before the end of February 2027.

The source: “GHK-Cu (except for injectable routes of administration) will be added back to category 1”

DEA schedule

It is not a federally controlled substance: its name is not in the DEA’s schedules (21 CFR Part 1308) or on the DEA’s alphabetical list of controlled substances.

Sport (WADA)

Until December 31, 2026: The 2026 Prohibited List doesn’t name GHK-Cu. S0 bans any substance not covered elsewhere on the list that has “no current approval by any governmental regulatory health authority for human therapeutic use”; whether that reaches it turns on its approval outside the United States, which this page doesn’t cover. From January 1, 2027: WADA’s 2027 list adds “peptides” to S0’s examples of non-approved substances, and its explanatory note says a peptide not named on the list “may still be prohibited”. It still doesn’t name GHK-Cu, and whether S0 reaches it still turns on its approval outside the United States.

How it is sold when it isn’t approved

FDA has warned companies that sold unapproved GLP-1 drugs labeled “for research purposes” or “not for human consumption” to consumers with dosing instructions, and calls that label false. FDA’s page names GLP-1 drugs; a research label is not an FDA approval of any kind.

The source: falsely labeled “for research purposes” or “not for human consumption.”

What this means and doesn’t

This page reports what the agencies’ own pages said about GHK-Cu in the United States when we read them on November 18, 2026. These are records of regulators, not study evidence; for what the research shows, see the compound page.

It is not legal advice, and it doesn’t cover state laws or other countries, whose rules differ. Agencies change their lists, so each fact carries its date and a link to the page it came from.

Questions

  • Is GHK-Cu FDA approved?

    GHK-Cu has no FDA-approved drug: Drugs@FDA lists no application for it.

  • Is GHK-Cu a controlled substance?

    It is not a federally controlled substance: its name is not in the DEA’s schedules (21 CFR Part 1308) or on the DEA’s alphabetical list of controlled substances.

  • Is GHK-Cu banned in sport?

    Until December 31, 2026: The 2026 Prohibited List doesn’t name GHK-Cu. S0 bans any substance not covered elsewhere on the list that has “no current approval by any governmental regulatory health authority for human therapeutic use”; whether that reaches it turns on its approval outside the United States, which this page doesn’t cover. From January 1, 2027: WADA’s 2027 list adds “peptides” to S0’s examples of non-approved substances, and its explanatory note says a peptide not named on the list “may still be prohibited”. It still doesn’t name GHK-Cu, and whether S0 reaches it still turns on its approval outside the United States.

  • What does FDA say about compounding GHK-Cu?

    FDA splits GHK-Cu by route. Its injectable form was in category 2 and its nominations were withdrawn. Its other routes (on the skin, for example) are back in category 1, substances under evaluation, on FDA’s list updated May 14, 2026, and FDA says it will ask its Pharmacy Compounding Advisory Committee about GHK-Cu before the end of February 2027.

  • What does FDA say about the “research use only” label?

    FDA has warned companies that sold unapproved GLP-1 drugs labeled “for research purposes” or “not for human consumption” to consumers with dosing instructions, and calls that label false. FDA’s page names GLP-1 drugs; a research label is not an FDA approval of any kind.

Read next

Track it in the app

PepVault for iPhone

Keep your own record in PepVault

Log your doses and vials, with a reminder for the next one.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo